Ocrelizumab study for relapsing MS in African Americans and Caucasians
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at how ocrelizumab works in people with relapsing-remitting multiple sclerosis (MS), and it specifically includes African American and Caucasian participants. Your neurologist may already be choosing ocrelizumab as the best standard treatment for you, and the study then follows you with medical visits and MRI scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your neurologist plans to start ocrelizumab and it’s your best standard MS medicine choice
- You’re 18 to 60 years old (and can sign informed consent)
- You self-identify as African American or Caucasian
- You have relapsing-remitting MS (not a different MS type) and your disability score is 0 to 6
- You can get MRI scans and you’re able to tolerate scans without severe claustrophobia
- You should not be pregnant and must be willing to follow study rules on recent relapse/steroid use
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how ocrelizumab, a medication for MS, affects immune cells in your lymph nodes. It may help doctors understand how the drug works and why it helps some people more than others.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
This study looks at how well the injected form of ocrelizumab works for people with relapsing-remitting multiple sclerosis (RRMS) in everyday care. It aims to understand the treatment's effects and side effects outside of a clinical trial setting.
This trial tests an injectable medication called ocrelizumab for children and teenagers with relapsing-remitting multiple sclerosis. The goal is to see if it is safe and how well it works to control the disease.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
Hear when a new Multiple Sclerosis, Relapsing-Remitting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.